

23 JAN 2006
Approved for use through 03/31/2006. OMB 0651-0032.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
---------------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)Inventor one: Zaihui ZhangCitizen of: CanadaSignature: [Signature]Date: Dec. 6, 2005Inventor two: Timothy S. DaynardCitizen of: Canada

Signature: _____

Date: _____

Inventor three: Shisen WangCitizen of: Canada

Signature: _____

Date: _____

Inventor four: Xinyao DuCitizen of: Canada

Signature: _____

Date: _____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.418USPC

BEST AVAILABLE COPY

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five: Gregory B. Chopiuk Citizen of: Canada

Signature: _____ Date: _____

Inventor six: Jun Yan Citizen of: Canada

Signature: _____ Date: _____

Inventor seven: Jianxin Chen Citizen of: Canada

Signature: _____ Date: _____

Inventor eight: Serguei V. Sviridov Citizen of: Canada / Belorussia

Signature: _____ Date: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention **PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE
AS THERAPEUTIC AGENTS**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: Zaihui Zhang Citizen of: Canada

Signature: _____ Date: _____

Inventor two: Timothy S. Daynard Citizen of: Canada

Signature:  Date: December 2, 2005

Inventor three: Shisen Wang Citizen of: Canada

Signature: _____ Date: _____

Inventor four: Xinyao Du Citizen of: Canada

Signature: _____ Date: _____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Docket No. 540057.418USPC

BEST AVAILABLE COPY

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**

Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five: Gregory B. Chopiuk Citizen of: Canada

Signature: _____ Date: _____

Inventor six: Jun Yan Citizen of: Canada

Signature: _____ Date: _____

Inventor seven: Jianxin Chen Citizen of: Canada

Signature: _____ Date: _____

Inventor eight: Serguei V. Sviridov Citizen of: Canada / Belorussia

Signature: _____ Date: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

WANG

EXPRESS MAIL NO. EV529783299US

Approved for use through 03/31/2006. OMB 0651-0032.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
---------------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)Inventor one: Zaihui Zhang Citizen of: Canada

Signature: _____ Date: _____

Inventor two: Timothy S. Daynard Citizen of: Canada

Signature: _____ Date: _____

Inventor three: Shisen Wang Citizen of: CanadaSignature: Shisen Wang Date: Nov 29, 2005Inventor four: Xinyao Du Citizen of: Canada

Signature: _____ Date: _____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.418USPC

BEST AVAILABLE COPY

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five:	<u>Gregory B. Chopiuk</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
<hr/>			
Inventor six:	<u>Jun Yan</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
<hr/>			
Inventor seven:	<u>Jianxin Chen</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
<hr/>			
Inventor eight:	<u>Serguei V. Sviridov</u>	Citizen of:	<u>Canada / Belorussia</u>
Signature:	<u></u>	Date:	<u></u>

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

DU

Approved for use through 03/31/2006. OMB 0651-0032.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	PYRAZOLYL BENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
--------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);


I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one:	<u>Zaihui Zhang</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor two:	<u>Timothy S. Daynard</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor three:	<u>Shisen Wang</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor four:	<u>Xinyao Du</u>	Citizen of:	<u>Canada</u>
Signature:		Date:	<u>Dec. 2, 2005</u>

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.418USPC

BEST AVAILABLE COPY

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**

Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five: Gregory B. Chopiuk Citizen of: Canada

Signature: _____ Date: _____

Inventor six: Jun Yan Citizen of: Canada

Signature: _____ Date: _____

Inventor seven: Jianxin Chen Citizen of: Canada

Signature: _____ Date: _____

Inventor eight: Serguei V. Sviridov Citizen of: Canada / Belorussia

Signature: _____ Date: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

Chopra

Approved for use through 03/31/2006. OMB 0651-0032.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
--------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: Zaihui Zhang Citizen of: Canada

Signature: _____ Date: _____

Inventor two: Timothy S. Daynard Citizen of: Canada

Signature: _____ Date: _____

Inventor three: Shisen Wang Citizen of: Canada

Signature: _____ Date: _____

Inventor four: Xinyao Du Citizen of: Canada


Signature: _____ Date: _____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Docket No. 540057.418USPC

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five:	<u>Gregory B. Chopluk</u>	Citizen of:	<u>Canada</u>
Signature:		Date:	<u>12/20/2005</u>
Inventor six:	<u>Jun Yan</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
Inventor seven:	<u>Jianxin Chen</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
Inventor eight:	<u>Serguei V. Sviridov</u>	Citizen of:	<u>Canada / Belorussia</u>
Signature:	<u></u>	Date:	<u></u>

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

BEST AVAILABLE COPY

YAN

EXPRESS MAIL NO. EV529783299US

Approved for use through 03/31/2006. OMB 0651-0032.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	PYRAZOLYL BENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
---------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one:	<u>Zaihui Zhang</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor two:	<u>Timothy S. Daynard</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor three:	<u>Shisen Wang</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____
Inventor four:	<u>Xinyao Du</u>	Citizen of:	<u>Canada</u>
Signature:	_____	Date:	_____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Docket No. 540057.418USPC


**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**

Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five: Gregory B. Chopiuk Citizen of: Canada

Signature: _____ Date: _____

Inventor six: Jun Yan Citizen of: CanadaSignature:  Date: Dec. 02, 2005Inventor seven: Jianxin Chen Citizen of: Canada

Signature: _____ Date: _____

Inventor eight: Serguei V. Sviridov Citizen of: Canada / Belorussia

Signature: _____ Date: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

BEST AVAILABLE COPY

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
---------------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
- ☒ as amended on January 21, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: <u>Zaihui Zhang</u>	Citizen of: <u>Canada</u>
-----------------------------------	---------------------------

Signature: _____	Date: _____
------------------	-------------

Inventor two: <u>Timothy S. Daynard</u>	Citizen of: <u>Canada</u>
---	---------------------------

Signature: _____	Date: _____
------------------	-------------

Inventor three: <u>Shisen Wang</u>	Citizen of: <u>Canada</u>
------------------------------------	---------------------------

Signature: _____	Date: _____
------------------	-------------

Inventor four: <u>Xinyao Du</u>	Citizen of: <u>Canada</u>
---------------------------------	---------------------------

Signature: _____	Date: _____
------------------	-------------


☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.418USPC

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five:	<u>Gregory B. Chopluk</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
Inventor six:	<u>Jun Yan</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u></u>
Inventor seven:	<u>Jianxin Chen</u>	Citizen of:	<u>Canada</u>
Signature:	<u></u>	Date:	<u>Dec. 12, 2005</u>
Inventor eight:	<u>Serguei V. Sviridov</u>	Citizen of:	<u>Canada / Belorussia</u>
Signature:	<u></u>	Date:	<u></u>

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
---------------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)Inventor one: Zaihui Zhang Citizen of: Canada

Signature: _____ Date: _____

Inventor two: Timothy S. Daynard Citizen of: Canada

Signature: _____ Date: _____

Inventor three: Shisen Wang Citizen of: Canada

Signature: _____ Date: _____

Inventor four: Xinyao Du Citizen of: Canada

Signature: _____ Date: _____

☒ Additional inventors or a legal representative are being named on one additional form attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Docket No. 540057.418USPC

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****ADDITIONAL INVENTOR(S)
Supplemental Sheet**Page 2 of 2

FULL NAME OF INVENTOR(S)

Inventor five: Gregory B. Chopiuk Citizen of: Canada

Signature: _____ Date: _____

Inventor six: Jun Yan Citizen of: Canada

Signature: _____ Date: _____

Inventor seven: Jianxin Chen Citizen of: Canada

Signature: _____ Date: _____

Inventor eight: Serguei V. Sviridov Citizen of: Canada / BelorussiaSignature:  Date: Nov 30, 2005☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

BEST AVAILABLE COPY

ELECTION AND POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/521,948, U.S. National Phase of PCT/CA03/001078 filed July 23, 2003
	First Named Inventor	Zaihui Zhang
	Title	PYRAZOLYL BENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
	Art Unit	
	Examiner Name	
	Attorney Docket Number	540057.418USPC

I hereby appoint:

☒ Practitioners at Seed IP Law Group PLLC, Customer Number: **00500**

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above (and any continuation/divisional applications therefrom), and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country					
Telephone		Fax			

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ As assignee of record of the entire interest I/we hereby elect, under 37 CFR 3.71, to prosecute the application to the exclusion of the inventor(s).

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Jennifer Kaufman-Shaw</i>	Date	January 12, 2006
Name	Jennifer Kaufman-Shaw		
Title and Company (Assignee)	Chief Patent Counsel QLT Inc.		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 540057.418USPC

BEST AVAILABLE COPY

PTO/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Zaihui Zhang et al.

Application No: 10/521,948, U.S. National Phase of PCT/CA03/001078
filed July 23, 2003

Entitled: **PYRAZOLYL BENZOTHAZOLE DERIVATIVES AND THEIR USE
AS THERAPEUTIC AGENTS**

QLT Inc. a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____%

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above.
The assignment was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the
current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title noted in B above are
attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be
submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the
records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

January 12, 2006

Date

Jennifer Kaufman-Shaw

Chief Patent Counsel

Typed or printed name

604-707-7519

Telephone Number

Jennifer Kaufman-Shaw
Signature

Chief Patent Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 540057.418USPC 563053

BEST AVAILABLE COPY

Express Mail No. EV529783299US

ASSIGNMENT

THIS ASSIGNMENT, by

Zaihui Zhang, having a mailing address of:
4038 MacDonald Street, Vancouver, British Columbia, Canada V6L 2N9;

COPY

Timothy S. Daynard, having a mailing address of:
1836 West 62nd Avenue, Vancouver, British Columbia, Canada V6P 2G4;

Shisen Wang, having a mailing address of:
2550 Raven Court, Coquitlam, British Columbia, Canada V3E 2J2;

Xinyao Du, having a mailing address of:
69-12551 Cambie Road, Richmond, British Columbia, Canada V6V 2A4;

Gregory B. Chopiuk, having a mailing address of:
803 – 2055 Pendrell Street, Vancouver, British Columbia, Canada V6G 1T9;

Jun Yan, having a mailing address of:
819 Alderson Avenue, Coquitlam, British Columbia, Canada V3K 1V3;

Jianxin Chen, having a mailing address of:
3948 West 18th Avenue, Vancouver, British Columbia, Canada V6S 1B7;

Serguei V. Sviridov, having a mailing address of:
1904 – 5885 Olive Avenue, Burnaby, British Columbia, Canada V5H 4N8

(hereinafter referred to as the Assignors), witnesseth:

WHEREAS, said Assignors have invented certain new and useful improvements in **PYRAZOLYLBENZOTHAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS**, set forth in an application for Letters Patent of the United States filed and assigned Application Serial No. **10/521,948**. This application is a national stage application filed under 35 U.S.C. 371 of International Application No. PCT/CA03/001078, accorded an International Filing Date of July 23, 2003; which claims the benefit of U.S. Provisional Patent Application No. 60/398,504 filed July 24, 2002; and

WHEREAS, **QLT Inc.**, a corporation duly organized under and pursuant to the laws of the Province of British Columbia and having its principal place of business at 887 Great Northern Way, Vancouver, British Columbia, Canada V5T 4T5 (hereinafter referred to as the Assignee) is desirous of acquiring the Assignors' entire right, title and interest in and to said invention and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, said Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said Assignee, its successors, legal representatives and assigns, their entire right, title and interest in and to the above-mentioned invention, application for Letters Patent and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said applications, or reissues or extensions of said Letters Patent or Patents, and all rights under

the International Convention for the Protection of Industrial Property, including the right to file foreign applications directly in the name of Assignee and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treat or otherwise, said invention, application and all Letters Patent on said invention to be held and enjoyed by said Assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors, had this sale and assignment not been made.

AND for the same consideration, said Assignors hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said Assignors are the sole and lawful owners of their entire right, title and interest in and to said inventions and applications, above-mentioned, and that the same are unencumbered and that said Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said Assignors hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that said Assignors will, whenever counsel of said Assignee, or the counsel of its successor, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said applications, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns.

AND said Assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said Assignee as the Assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said Assignee, its successors, legal representatives and assigns.

This Assignment is effective as of July 23, 2003.

Dec. 6, 2005 Zaihui Zhang
Date Zaihui Zhang


I do hereby certify that Zaihui Zhang who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that s/he executed the same in my presence for the uses and purposes therein expressed.

Thong Trinh
Signature of Notary Public
THONG NGOC TRINH
BARRISTER & SOLICITOR
Printed Name


My appointment does not expire.

DECEMBER 2 2005

Date


Timothy S. Daynard

I do hereby certify that Timothy S. Daynard who is personally known to me ~~or proved to me on the basis of satisfactory evidence~~ to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.


Signature of Notary Public

Printed Name

My appointment does not expire.

Sandra R. MacKay
Barrister & Solicitor
Notary Public
British Columbia
887 Great Northern Way
Vancouver, B.C.
Canada V5T 4T5

Dec 2, 2005
Date

Shisen Wang
Shisen Wang

I do hereby certify that ~~Shisen Wang~~ ^{Shisen Wang} who is personally known to me ~~or proved to me on the~~ basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that s/he executed the same in my presence for the uses and purposes therein expressed.


Signature of Notary Public

Printed Name

My appointment does not expire.


Sandra R. MacKay
Barrister & Solicitor
Notary Public
British Columbia
887 Great Northern Way
Vancouver, B.C.
Canada V5T 4T5

Dec. 2, 2005

Date

Xinyao Du

I do hereby certify that Xinyao Du who is personally known to me/[✓]or [✓]proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that s/he executed the same in my presence for the uses and purposes therein expressed.


Signature of Notary Public

Printed Name

My appointment does not expire


Sandra H. MacKay
Barrister & Solicitor
Notary Public
British Columbia
887 Great Northern Way
Vancouver, B.C.
Canada V5T 4T5

12/20/2005
Date



Gregory B. Chopiuk


I do hereby certify that Gregory B. Chopiuk who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.



Signature of Notary Public
Jill R. Clarke

Printed Name

~~My appointment does not expire.~~



Dec. 02, 2005
Date

Jun Yan
Jun Yan

I do hereby certify that Jun Yan who is personally known to me ~~or proved to me on the basis of~~
~~satisfactory evidence~~ to be the person whose name is subscribed to this Assignment, did appear before me
and sign this Assignment and did statutorily declare before me upon oath that s/he executed the same in
my presence for the uses and purposes therein expressed.

Sandra R. MacKay
Signature of Notary Public

Printed Name


My appointment does not expire.

Sandra R. MacKay
Barrister & Solicitor
Notary Public
British Columbia
887 Great Northern Way
Vancouver, B.C.
Canada V5T 4T5

Dec. 12, 2005
Date

Jianxin Chen
Jianxin Chen

I do hereby certify that Jianxin Chen who ~~is personally known to me~~ or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that s/he executed the same in my presence for the uses and purposes therein expressed.



Signature of Notary Public

Printed Name


My appointment does not expire.


FILIP de SAGHER
NOTARY PUBLIC
2515 ALMA STREET
VANCOUVER, B.C. V6R 3R8
TEL: 604-221-4343

ATTESTED ONLY, WITHOUT PREJUDICE
AS TO FORM AND SUBSTANCE
NO ADVICE OR OPINION RENDERED

Dec 6, 2005 
Date Serguei V. Sviridov

I do hereby certify that Serguei V. Sviridov who is personally known to me/or proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this Assignment, did appear before me and sign this Assignment and did statutorily declare before me upon oath that he executed the same in my presence for the uses and purposes therein expressed.




Signature of Notary Public
THONG NGOC TRINH
BARRISTER & SOLICITOR

Printed Name

My appointment does not expire.

540057.418USPC
563001_1.DOC